MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

Du, L; Wang, DY; Wei, XQ; Liu, C; Xiao, ZL; Qian, W; Song, YH; Hou, XH

Hou, XH (通讯作者),Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Div Gastroenterol, Wuhan 430022, Peoples R China.

BMC GASTROENTEROLOGY, 2022; 22 (1):

Abstract

Background Malignant ascites is a manifestation of end stage events in a variety of cancers and is associated with significant morbidity. Epigenetic m......

Full Text Link